146 related articles for article (PubMed ID: 30241879)
1. In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis.
Omran SM; Taghizadeh-Armaki M; Zarrinfar H; Hedayati MT; Abastabar M; Moqarabzadeh V; Ansari S; Saber S; Hoseinnejad A; Miri A; Verweij PE; Seyedmousavi S
J Infect Chemother; 2019 Feb; 25(2):157-160. PubMed ID: 30241879
[TBL] [Abstract][Full Text] [Related]
2. Genetic Diversity and
Taghizadeh-Armaki M; Hedayati MT; Ansari S; Omran SM; Saber S; Rafati H; Zoll J; van der Lee HA; Melchers WJG; Verweij PE; Seyedmousavi S
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264849
[No Abstract] [Full Text] [Related]
3. In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen.
Khodavaisy S; Badali H; Hashemi SJ; Aala F; Nazeri M; Nouripour-Sisakht S; Sorkherizi MS; Amirizad K; Aslani N; Rezaie S
J Mycol Med; 2016 Jun; 26(2):116-121. PubMed ID: 26948143
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Rudramurthy SM; Chakrabarti A; Geertsen E; Mouton JW; Meis JF
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):370-7. PubMed ID: 21937186
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.
Badiee P; Boekhout T; Zarei Mahmoudabadi A; Mohammadi R; Ayatollahi Mousavi SA; Najafzadeh MJ; Soltani J; Hashemi J; Diba K; Ghadimi-Moghadam A; Salimi-Khorashad AR; Shokohi T; Amin Shahidi M; Ghasemi F; Jafarian H
Microbiol Spectr; 2022 Jun; 10(3):e0253921. PubMed ID: 35579442
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.
Baghi N; Shokohi T; Badali H; Makimura K; Rezaei-Matehkolaei A; Abdollahi M; Didehdar M; Haghani I; Abastabar M
Med Mycol; 2016 Oct; 54(7):757-63. PubMed ID: 27118804
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
8. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
Al-Wathiqi F; Ahmad S; Khan Z
BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
[TBL] [Abstract][Full Text] [Related]
9. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.
Bedin Denardi L; Hoch Dalla-Lana B; Pantella Kunz de Jesus F; Bittencourt Severo C; Morais Santurio J; Zanette RA; Hartz Alves S
Braz J Infect Dis; 2018; 22(1):30-36. PubMed ID: 29172033
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.
Seyedmousavi S; Samerpitak K; Rijs AJ; Melchers WJ; Mouton JW; Verweij PE; de Hoog GS
Antimicrob Agents Chemother; 2014 Jun; 58(6):3285-92. PubMed ID: 24687495
[TBL] [Abstract][Full Text] [Related]
12. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
Hadrich I; Makni F; Neji S; Cheikhrouhou F; Bellaaj H; Elloumi M; Ayadi A; Ranque S
Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
[TBL] [Abstract][Full Text] [Related]
14. Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.
Abastabar M; Al-Hatmi AMS; Vafaei Moghaddam M; de Hoog GS; Haghani I; Aghili SR; Shokohi T; Hedayati MT; Daie Ghazvini R; Kachuei R; Rezaei-Matehkolaei A; Makimura K; Meis JF; Badali H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530844
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of aflatoxigenic and non-aflatoxigenic Aspergillus flavus strains to conventional antifungal agents.
Fattahi A; Zaini F; Kordbacheh P; Hashemi SJ; Mahmoudi M; Safara M
Acta Med Iran; 2012; 50(12):798-804. PubMed ID: 23456520
[TBL] [Abstract][Full Text] [Related]
17. In vitro interactions of azoles and echinocandins against clinical strains of Aspergillus flavus.
Denardi LB; Oliveira V; de Jesus FPK; Dalla-Lana BH; Santurio JM; Zanette RA; Alves SH
Med Mycol; 2018 Nov; 56(8):1006-1011. PubMed ID: 29294129
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India.
Sharma C; Kumar R; Kumar N; Masih A; Gupta D; Chowdhary A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311090
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
